14 completed, 5 active not recruiting, 4 terminated, 2 recruiting. 28 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Completed 14, Active not recruiting 5, Terminated 4, Recruiting 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Unknown 1 |
Follow Leuprolide Acetate: new trials by email Literature Review of Leuprolide Acetate trials Research Report on Leuprolide Acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate Relugolix, Leuprolide Acetate - Prostate Cancer | Phase 3 | Completed | Sumitomo Pharma America, Inc. | 387 | 2023-01-28 | 2026-06-15 |
| A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy Enzalutamide, Rucaparib camsylate, Placebo - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 61 | 2021-10-14 | 2026-02-05 |
| Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study Darolutamide, Goserelin Acetate, Leuprolide Acetate - Prostate Carcinoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 27 | 2021-03-01 | 2026-07-28 |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 804 | 2020-10-08 | 2026-11-13 |
| GnRH Agonist at Embryo Transfer: IVF Outcomes Saline Solution for Injection, Leuprolide Acetate - Infertility, Infertility, Female | Phase 3 | Withdrawn | Maimonides Medical Center | 2019-04-15 | 2019-04-16 | |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Abiraterone, Bicalutamide, Degarelix - Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 1273 | 2018-09-24 | 2026-10-08 |
| A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer Relugolix, Leuprolide Acetate - Prostate Cancer | Phase 3 | Completed | Myovant Sciences GmbH | 1134 | 2017-04-18 | 2022-01-18 |
| Management of Castration-Resistant Prostate Cancer with Oligometastases Leuprolide Acetate, Goserelin Acetate, Triptorelin - Castration-resistant Prostate Cancer Patients with Oligometastases | Phase 2 / Phase 3 | Active not recruiting | Sir Mortimer B. Davis - Jewish General Hospital | 102 | 2016-10-01 | 2024-12-04 |
| Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women Goserelin, Tamoxifen, Aromatase Inhibitors - Breast Cancer | Phase 3 | Unknown | First Affiliated Hospital, Sun Yat-Sen University | 680 | 2016-03-30 | 2023-01-17 |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label - Hormone Sensitive Prostate Cancer, Prostate Cancer | Phase 3 | Active not recruiting | Pfizer | 1068 | 2014-12-17 | 2026-10-26 |
| S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer anastrozole, everolimus, exemestane - Breast Cancer | Phase 3 | Active not recruiting | SWOG Cancer Research Network | 1939 | 2013-09-12 | 2026-10-23 |
| Post-operative or Early Salvage XRT and ADT for High Risk PCa antiandrogen therapy, leuprolide acetate, 3-dimensional conformal radiation therapy - Prostate Cancer | Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 87 | 2009-10-01 | 2014-07-04 |
| Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer bicalutamide, buserelin, flutamide - Prostate Cancer | Phase 3 | Terminated | NCIC Clinical Trials Group | 48 | 2008-06-02 | 2023-08-04 |
| A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg - Puberty, Precocious | Phase 3 | Completed | Abbott | 84 | 2008-06-01 | 2011-11-02 |
| Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients leuprolide acetate - Prostate Cancer | Phase 3 | Terminated | GP-Pharm | 20 | 2008-05-01 | 2010-09-09 |
| Prevention of Obesity in Women Via Estradiol Regulation leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training - Obesity | Phase 3 | Completed | University of Colorado, Denver | 79 | 2008-05-01 | 2025-04-01 |
| RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery bicalutamide, goserelin acetate, leuprolide acetate - Gastrointestinal Complications, Prostate Cancer | Phase 3 | Completed | University College, London | 4236 | 2007-11-01 | 2023-11-13 |
| PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial Leuprolide acetate - Fertility Preservation, Cancer | Phase 3 | Completed | Ottawa Hospital Research Institute | 30 | 2007-01-01 | 2017-04-05 |
| Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer leuprolide acetate - Prostate Cancer | Phase 3 | Completed | GP-Pharm | 120 | 2005-09-01 | 2007-11-14 |
| Lupron Sex Offender Therapy leuprolide acetate - Pedophilia | Phase 2 / Phase 3 | Unknown | Schober, Justine, M.D. | 10 | 2001-10-01 | 2005-09-22 |
Showing 20 of 28. Sign in to see all of them.
Prostatic Neoplasms (18) · Breast Neoplasms (4) · Neoplasms (3) · Breast Neoplasms, Male (1) · Disease Susceptibility (1) · Infertility (1) · Infertility, Female (1) · Infertility, Male (1) · Metabolic Syndrome (1) · Obesity (1) · Pedophilia (1) · Puberty, Precocious (1) · Sexual Dysfunction, Physiological (1)
NCIC Clinical Trials Group (3) · ECOG-ACRIN Cancer Research Group (2) · GP-Pharm (2) · SWOG Cancer Research Network (2) · Abbott (1) · Alliance for Clinical Trials in Oncology (1) · Eastern Cooperative Oncology Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Institute of Cancer Research, United Kingdom (1) · M.D. Anderson Cancer Center (1) · Maimonides Medical Center (1) · Myovant Sciences GmbH (1) · National Cancer Institute (NCI) (1) · Ottawa Hospital Research Institute (1)
United States (18) · Canada (9) · United Kingdom (6) · Austria (3) · France (3) · Italy (3) · Slovakia (3) · Spain (3) · Australia (2) · Brazil (2) · China (2) · Denmark (2) · Finland (2) · Germany (2) · Netherlands (2)
A. O. Sartor, MD (1) · Alicia K Morgans (1) · Antonios Likourezos, M.P.H., M.A. (1) · Arpit Rao, MD (1) · Brian Chapin (1) · Celestia S. Higano, MD (1) · Christopher Parker, MD (1) · Curtis A. Pettaway, MD (1) · David G. McGowan, MD (1) · George Wilding, MD (1) · Helena Earl, MBBS, PhD, FRCP (1) · John R. Yarnold, MD, FRCR (1) · Justine M Schober, MD (1) · Kim N. Chi, MD (1) · Laurence H. Klotz, MD (1)
PMID 38421243, PMID 10663329, PMID 17405995, PMID 17405996, PMID 19167733, PMID 20435244, PMID 21751904, PMID 22056152, PMID 22344198, PMID 22931259, PMID 25691677, PMID 25732157, PMID 26014295, PMID 29631362, PMID 31899823, PMID 33002429, PMID 33002431, PMID 33390282, PMID 34385241, PMID 34481017, PMID 35587650, PMID 35810050, PMID 37119051, PMID 37713020, PMID 37851874, PMID 38320143, PMID 38320501, PMID 38421252, PMID 38583574, PMID 38763153, PMID 38763154, PMID 38833643, PMID 39621968, PMID 40140551, PMID 40907514, PMID 41124201, PMID 41349040, PMID 41364813, PMID 41824265, PMID 42333826
U10CA180820 (2), 2017 (1), P30CA016672 (1), R01AG018198 (1), U10CA032102 (1), U10CA180821 (1), U10CA180888 (1)